Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saroj Niraula

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Cancer|June 3, 2019
Strategizing health technology assessment for containment of cancer drug costs in a universal health care system: Case of the pan-Canadian Oncology Drug ReviewSaroj Niraula
Breast (Edinburgh, Scotland)|December 5, 2018
Why upfront use of CDK inhibitors for the treatment of advanced breast cancer may be wasteful, and how we can increase their valueSaroj Niraula
Cancer Medicine|September 30, 2016
Screening mammography: sparing the emperor's blushesSaroj Niraula
Health Affairs (Project Hope)|August 4, 2025
Global Cancer Care: An Unfinished PromiseSaroj Niraula
Cancer Treatment Reviews|April 22, 2025
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertaintySaroj Niraula
Cancer Treatment Reviews|October 4, 2016
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategySaroj Niraula, Alberto Ocana
Breast Cancer Research and Treatment|September 22, 2018
Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trialsSaroj Niraula, Bishal Gyawali
Ecancermedicalscience|May 11, 2018
Cancer treatment in the last 6 months of life: when inaction can outperform actionBishal Gyawali, Saroj Niraula
Journal of the National Comprehensive Cancer Network : JNCCN|December 15, 2018
New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review RecommendationsSaroj Niraula, Zoann Nugent
Cancer Treatment Reviews|September 2, 2017
Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trialsBishal Gyawali, Saroj Niraula
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Cancer|June 3, 2019
Strategizing health technology assessment for containment of cancer drug costs in a universal health care system: Case of the pan-Canadian Oncology Drug ReviewSaroj Niraula
Breast (Edinburgh, Scotland)|December 5, 2018
Why upfront use of CDK inhibitors for the treatment of advanced breast cancer may be wasteful, and how we can increase their valueSaroj Niraula
Cancer Medicine|September 30, 2016
Screening mammography: sparing the emperor's blushesSaroj Niraula
Health Affairs (Project Hope)|August 4, 2025
Global Cancer Care: An Unfinished PromiseSaroj Niraula
Cancer Treatment Reviews|April 22, 2025
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertaintySaroj Niraula
Cancer Treatment Reviews|October 4, 2016
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategySaroj Niraula, Alberto Ocana
Breast Cancer Research and Treatment|September 22, 2018
Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trialsSaroj Niraula, Bishal Gyawali
Ecancermedicalscience|May 11, 2018
Cancer treatment in the last 6 months of life: when inaction can outperform actionBishal Gyawali, Saroj Niraula
Journal of the National Comprehensive Cancer Network : JNCCN|December 15, 2018
New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review RecommendationsSaroj Niraula, Zoann Nugent
Cancer Treatment Reviews|September 2, 2017
Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trialsBishal Gyawali, Saroj Niraula
Pageof 4